Skip to main content

Table 2 Seropositivity risk after two doses of measles vaccine by age at first vaccination

From: Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis

Author, year (strain) (ref)NaSeropositivity dfnbSeropositivity risk by age at MVC1 [95%CI]
< 667–8910–1112
Soerensen, 1985 (Schwarz) [92]1111+  0.80 [0.77–0.82]0.90 [0.83–0.98]0.96 [0.90–1] 
McGraw, 1986 (Moraten) [85]52+  0.95 [0.85–1]0.89 [0.76–1]1.00 [−]
Gans, 2001 (Moraten) [6]31+ 1.00 [−] 1.00 [−]  
Gans, 2004 (Moraten) [93]50+ 0.86 [0.74–0.99] 0.90 [0.78–1]  
Vesikari, 2012 (Moraten) [69]1364+   0.95 [0.93–0.97]0.98c [0.96–0.99]0.99 [0.97–1]
Martins, 2014 (EZ) [74]655+0.97 [0.95–0.99]  0.99 [0.98–1]  
He, 2014 (Hu191) [70]206+  1.00d [−]  1.00 [−]
Youwang, 2001 (Hu191) [132]764-fold 0.40 [0.15–0.65]0.52e [0.40–0.65]
  1. Abbreviations: CI Confidence interval, E-Z Edmonston-Zagreb, NR Not reported, MCV1 dose one of measles-containing vaccine
  2. a Number of cases for the calculation of the age effect
  3. b + = seropositivity among all participants; 4-fold = fourfold increase in antibody titers
  4. c 11 months
  5. d 8 months
  6. e 8 to 15 months